New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
12:13 EDTPFEPfizer to submit palbociclib NDA based on results of PALOMA-1 trial
Pfizer announced that it will submit a New Drug Application, or NDA, with the Food and Drug Administration for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer. Pfizer expects to submit the NDA early in Q3 of this year. This decision was based on discussions with the FDA regarding the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients. Palbociclib received Breakthrough Therapy designation from the FDA in April 2013, for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cance based on interim data from the PALOMA-1 trial, the company noted.
News For PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
07:35 EDTPFEPfizer issues to Repligen a notice of termination under 2012 license agreement
Subscribe for More Information
06:34 EDTPFEObama to propose $215M for major medical program, CNBC says
Subscribe for More Information
06:30 EDTPFEEli Lilly FY15 EPS guidance does not include 12c potential charge
Subscribe for More Information
January 29, 2015
08:15 EDTPFEOPKO Health, Pfizer receive regulatory clearance for global agreement
Subscribe for More Information
January 28, 2015
07:39 EDTPFEPfizer CEO says company not in need of big M&A deal, FT reports
Subscribe for More Information
January 27, 2015
07:16 EDTPFEPfizer drops 2.7% after FY15 outlook miss expectations
Subscribe for More Information
07:07 EDTPFEPfizer sees FY15 adjusted EPS $2.00-$2.10, consensus $2.18
Subscribe for More Information
07:01 EDTPFEPfizer reports Q4 adjusted EPS 54c, consensus 53c
Reports Q4 revenue $13.1B, consensus $12.9B.
January 26, 2015
16:15 EDTPFEPfizer commits to lower price for Prevenar 13 in developing countries
Subscribe for More Information
15:40 EDTPFENotable companies reporting before tomorrow's open
Subscribe for More Information
13:29 EDTPFEEarnings Preview: Pfizer set to report Q4 results as generics impact Celebrex
Subscribe for More Information
January 23, 2015
16:08 EDTPFETeva volatility elevated, Pfizer approached late last year, Bloomberg says
Teva (TEVA) overall option implied volatility of 25 compares to its 26-week average of 23 according to Track Data, suggesting large price movement into Pfizer (PFE) approach late last year, Bloomberg says.
16:04 EDTPFETeva rebuffed Pfizer approach late last year, Bloomberg says
Subscribe for More Information
January 22, 2015
11:23 EDTPFEPfizer says CHMP adopted positive opinion on Prevenar 13 expansion
Subscribe for More Information
January 21, 2015
12:30 EDTPFEGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use